

# Clinical trials of mitiglinide

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
<b>mitiglinide+voglibose vs insulin glargine</b>			
<b>GLORIA</b> [NCT00663884] n=NA follow-up: 16 weeks	combination therapy of 10 mg mitiglinide or 0.2mg voglibose versus insulin glargine	diabetic patients whose glycemic control were not enough despite administration of oral antidiabetic drug or insulin glargine	open Korea
<b>mitiglinide vs nateglinide</b>			
<b>Gao</b> [NCT00461617] n=291 follow-up: 20 weeks	mitiglinide 10 - 20 mg three times daily versus nateglinide 120 mg three times daily	Chinese type 2 diabetes mellitus patients	Parallel groups double-blind
<b>mitiglinide vs on top insulin glargine</b>			
<b>Kumashiro , 2007</b> n=NA follow-up:	mitiglinide versus on top of once daily insulin glargine	-	
<b>mitiglinide vs placebo (add on MET)</b>			
<b>NCT01037842</b> [NCT01037842] n=NA follow-up: 16 weeks	mitiglinide versus placebo	patients with type 2 diabetes who show inadequate glycemic control with metformin monotherapy	double-blind Korea
<b>EX-1510-CT-003</b> [NCT00519142] n=NA follow-up: 24 weeks	metformin + mitiglinide three times a day with meals versus (metformin + placebo for mitiglinide	patients with Type 2 diabetes mellitus not well controlled with metformin alone	double-blind US
<b>mitiglinide vs placebo (on top pioglitazone)</b>			
<b>Kaku , 2009</b> n=NA follow-up: 16 weeks	additional mitiglinide 5 or 10 mg tid versus placebo on top pioglitazone	Japanese type 2 diabetic patients who are insufficiently controlled by pioglitazone monotherapy	Parallel groups multicenter

More details and results :

- antidiabetic drugs for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q81>
- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>

- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- insulin secretagogues - Meglitinides (glinides) for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q549>

## References

### **GLORIA, 0:**

#### **Gao, 0:**

Gao X, , Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res ;37:812-21. [19589264]

#### **Kumashiro, 2007:**

Kumashiro N, Yoshihara T, Kanazawa Y, Shimizu T, Watada H, Tanaka Y, Fujitani Y, Kawamori R, Hirose T, Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. Endocr J 2007;54:163-6. [17185877]

#### **NCT01037842, :**

#### **EX-1510-CT-003, 0:**

#### **Kaku, 2009:**

Kaku K, Tanaka S, Origasa H, Kikuchi M, Akanuma Y, Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. Endocr J 2009;56:657-64. [19352048]

Entry terms: miti-glinide, KAD 1229, KAD-1229,